Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Poseida Therapeutics reports Q1 EPS (62c), consensus (63c) » 16:14
05/11/21
05/11
16:14
05/11/21
16:14
PSTX

Poseida Therapeutics

$8.48 /

+0.54 (+6.80%)

As of March 31 cash, cash…

As of March 31 cash, cash equivalents and short-term investments were $270.0M. "We are encouraged by our continued progress in Q1, building on the accomplishments from the prior year as we moved multiple programs forward to important inflection points, including our ongoing P-BCMA-101 and P-PSMA-101 CAR-T programs, on which we plan to provide further clinical updates later in the year," said Eric Ostertag, CEO of Poseida. "Additionally, we intend to advance two INDs in our allogeneic CAR-T portfolio this year, one for P-BCMA-ALLO1, targeting BCMA in relapsed/refractory multiple myeloma; and the other for P-MUC1C-ALLO1, targeting MUC1-C in a variety of solid tumor indications, including triple negative breast cancer and ovarian cancer. Though still early, initial clinical activity in patients with prostate cancer following treatment with P-PSMA-101 increases our excitement and confidence in the probability of success for this pan-solid tumor program."

ShowHide Related Items >><<
PSTX Poseida Therapeutics
$8.48 /

+0.54 (+6.80%)

PSTX Poseida Therapeutics
$8.48 /

+0.54 (+6.80%)

02/25/21 Piper Sandler
Poseida's 'very robust' R&D day highlights platform breadth, says Piper Sandler
02/24/21 Piper Sandler
Poseida should close meaningfully higher on update, says Piper Sandler
08/20/20 Piper Sandler
Poseida Therapeutics's P-BCMA-101 data expected by year-end, says Piper Sandler
08/17/20 Piper Sandler
Poseida Therapeutics' halt of P-PSMA-101 may have been preventable, says Piper
PSTX Poseida Therapeutics
$8.48 /

+0.54 (+6.80%)

  • 10
    Jul
PSTX Poseida Therapeutics
$8.48 /

+0.54 (+6.80%)

PSTX Poseida Therapeutics
$8.48 /

+0.54 (+6.80%)

Over a week ago
Hot Stocks
Autolus Therapeutics sees cash runway into 1H23 » 07:28
05/06/21
05/06
07:28
05/06/21
07:28
AUTL

Autolus Therapeutics

$5.22 /

-0.165 (-3.06%)

Autolus estimates that…

Autolus estimates that its current cash on hand will provide the Company with a cash runway into the first half of 2023.

ShowHide Related Items >><<
AUTL Autolus Therapeutics
$5.22 /

-0.165 (-3.06%)

AUTL Autolus Therapeutics
$5.22 /

-0.165 (-3.06%)

03/10/21 Redburn
Autolus Therapeutics downgraded to Neutral from Buy at Redburn
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral with $9 target at JPMorgan
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral from Overweight at JPMorgan
01/07/21 Truist
Autolus Therapeutics price target lowered to $15 from $30 at Truist
AUTL Autolus Therapeutics
$5.22 /

-0.165 (-3.06%)

  • 10
    Feb
Hot Stocks
Autolus Therapeutics announces key upcoming milestones » 07:27
05/06/21
05/06
07:27
05/06/21
07:27
AUTL

Autolus Therapeutics

$5.22 /

-0.165 (-3.06%)

Key Upcoming Clinical…

Key Upcoming Clinical Milestones: AUTO1 updates in 2021 on ALLCAR19 in patients with r/r B-NHL and longer term follow up of the fully enrolled r/r aALL cohort. AUTO1 - Currently enrolling a potentially pivotal Phase 1b/2 clinical trial in r/r adult ALL patients with data expected in 2022. Updates on Phase 1 programs AUTO1/22 in pediatric ALL, as well as AUTO4 in TRBC1+ Peripheral TCL, in 2021. Phase 1 trials are expected to be initiated in 2021 with AUTO1 in Primary CNS Lymphoma, AUTO5 in TRBC2+ Peripheral TCL, AUTO6NG in Neuroblastoma, and AUTO8 in Multiple Myeloma. First exploratory allogeneic program expected to enter the clinic in 2021.

ShowHide Related Items >><<
AUTL Autolus Therapeutics
$5.22 /

-0.165 (-3.06%)

AUTL Autolus Therapeutics
$5.22 /

-0.165 (-3.06%)

03/10/21 Redburn
Autolus Therapeutics downgraded to Neutral from Buy at Redburn
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral with $9 target at JPMorgan
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral from Overweight at JPMorgan
01/07/21 Truist
Autolus Therapeutics price target lowered to $15 from $30 at Truist
AUTL Autolus Therapeutics
$5.22 /

-0.165 (-3.06%)

  • 10
    Feb
Earnings
Autolus Therapeutics reports Q1 EPS (53c), consensus (60c) » 07:27
05/06/21
05/06
07:27
05/06/21
07:27
AUTL

Autolus Therapeutics

$5.22 /

-0.165 (-3.06%)

"We have had a…

"We have had a productive first quarter and are on track for multiple clinical read outs during the remainder of this year and into 2022," said Dr. Christian Itin, chief executive officer of Autolus. "We are excited by the unique characteristics of AUTO1 and encouraged by what we believe is the significant clinical benefit AUTO1 can offer for patients with relapsed/refractory Acute Lymphoblastic Leukemia. AUTO1 is being evaluated in the P1b/2 FELIX study in adult ALL patients with data expected in 2022. In addition, AUTO1 is being explored in patients with B-NHL and in primary CNS lymphoma, and we are also evaluating AUTO1/22 in pediatric ALL patients. Finally, several programs are expected to enter the clinic in 2021, including our next generation program AUTO6NG in Neuroblastoma, setting up clinical news flow for 2022 and beyond."

ShowHide Related Items >><<
AUTL Autolus Therapeutics
$5.22 /

-0.165 (-3.06%)

AUTL Autolus Therapeutics
$5.22 /

-0.165 (-3.06%)

03/10/21 Redburn
Autolus Therapeutics downgraded to Neutral from Buy at Redburn
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral with $9 target at JPMorgan
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral from Overweight at JPMorgan
01/07/21 Truist
Autolus Therapeutics price target lowered to $15 from $30 at Truist
AUTL Autolus Therapeutics
$5.22 /

-0.165 (-3.06%)

  • 10
    Feb
Conference/Events
Raymond James to hold a virtual summit » 09:23
04/22/21
04/22
09:23
04/22/21
09:23
AUTL

Autolus Therapeutics

$5.50 /

+0.3 (+5.77%)

, PSTX

Poseida Therapeutics

$8.93 /

+0.4 (+4.69%)

Oncology Virtual Summit…

Oncology Virtual Summit 2021 will be held on April 22.

ShowHide Related Items >><<
PSTX Poseida Therapeutics
$8.93 /

+0.4 (+4.69%)

AUTL Autolus Therapeutics
$5.50 /

+0.3 (+5.77%)

AUTL Autolus Therapeutics
$5.50 /

+0.3 (+5.77%)

03/10/21 Redburn
Autolus Therapeutics downgraded to Neutral from Buy at Redburn
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral with $9 target at JPMorgan
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral from Overweight at JPMorgan
01/07/21 Truist
Autolus Therapeutics price target lowered to $15 from $30 at Truist
PSTX Poseida Therapeutics
$8.93 /

+0.4 (+4.69%)

02/25/21 Piper Sandler
Poseida's 'very robust' R&D day highlights platform breadth, says Piper Sandler
02/24/21 Piper Sandler
Poseida should close meaningfully higher on update, says Piper Sandler
08/20/20 Piper Sandler
Poseida Therapeutics's P-BCMA-101 data expected by year-end, says Piper Sandler
08/17/20 Piper Sandler
Poseida Therapeutics' halt of P-PSMA-101 may have been preventable, says Piper
PSTX Poseida Therapeutics
$8.93 /

+0.4 (+4.69%)

AUTL Autolus Therapeutics
$5.50 /

+0.3 (+5.77%)

  • 10
    Feb
  • 10
    Jul
PSTX Poseida Therapeutics
$8.93 /

+0.4 (+4.69%)

PSTX Poseida Therapeutics
$8.93 /

+0.4 (+4.69%)

Conference/Events
William Blair biotech analysts to hold an analyst/industry conference call » 07:25
04/20/21
04/20
07:25
04/20/21
07:25
AUTL

Autolus Therapeutics

$5.24 /

-0.04 (-0.76%)

Biotech Analysts, along…

Biotech Analysts, along with Dr. Marks, Director of the Bristol Allogeneic Adult Bone Marrow Transplant Unit, will discuss Autolus' potentially pivotal Phase II FELIX study of AUTO1 in adult Acute Lymphoblastic Leukemia (ALL) on an Analyst/Industry conference call to be held on April 20 at 8 am.

ShowHide Related Items >><<
AUTL Autolus Therapeutics
$5.24 /

-0.04 (-0.76%)

AUTL Autolus Therapeutics
$5.24 /

-0.04 (-0.76%)

03/10/21 Redburn
Autolus Therapeutics downgraded to Neutral from Buy at Redburn
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral with $9 target at JPMorgan
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral from Overweight at JPMorgan
01/07/21 Truist
Autolus Therapeutics price target lowered to $15 from $30 at Truist
AUTL Autolus Therapeutics
$5.24 /

-0.04 (-0.76%)

  • 10
    Feb
Hot Stocks
Autolus Therapeutics receives ILAP designation from UK MHRA for AUTO4 » 07:09
04/20/21
04/20
07:09
04/20/21
07:09
AUTL

Autolus Therapeutics

$5.24 /

-0.04 (-0.76%)

Autolus Therapeutics…

Autolus Therapeutics announced that it has received innovative licensing and access pathway designation from the UK Medicines and Healthcare products Regulatory Agency for AUTO4 being studied in a Phase 1 study in TRBC1 positive Peripheral T Cell Lymphoma.

ShowHide Related Items >><<
AUTL Autolus Therapeutics
$5.24 /

-0.04 (-0.76%)

AUTL Autolus Therapeutics
$5.24 /

-0.04 (-0.76%)

03/10/21 Redburn
Autolus Therapeutics downgraded to Neutral from Buy at Redburn
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral with $9 target at JPMorgan
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral from Overweight at JPMorgan
01/07/21 Truist
Autolus Therapeutics price target lowered to $15 from $30 at Truist
AUTL Autolus Therapeutics
$5.24 /

-0.04 (-0.76%)

  • 10
    Feb
Conference/Events
William Blair biotech analysts to hold an analyst/industry conference call » 04:55
04/20/21
04/20
04:55
04/20/21
04:55
AUTL

Autolus Therapeutics

$5.24 /

-0.04 (-0.76%)

Biotech Analysts, along…

Biotech Analysts, along with Dr. Marks, Director of the Bristol Allogeneic Adult Bone Marrow Transplant Unit, will discuss Autolus' potentially pivotal Phase II FELIX study of AUTO1 in adult Acute Lymphoblastic Leukemia (ALL) on an Analyst/Industry conference call to be held on April 20 at 8 am.

ShowHide Related Items >><<
AUTL Autolus Therapeutics
$5.24 /

-0.04 (-0.76%)

AUTL Autolus Therapeutics
$5.24 /

-0.04 (-0.76%)

03/10/21 Redburn
Autolus Therapeutics downgraded to Neutral from Buy at Redburn
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral with $9 target at JPMorgan
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral from Overweight at JPMorgan
01/07/21 Truist
Autolus Therapeutics price target lowered to $15 from $30 at Truist
AUTL Autolus Therapeutics
$5.24 /

-0.04 (-0.76%)

  • 10
    Feb
Hot Stocks
Autolus Therapeutics announces appointment of Murphy as non-executive chairman » 07:22
04/19/21
04/19
07:22
04/19/21
07:22
AUTL

Autolus Therapeutics

$5.28 /

-0.25 (-4.52%)

Autolus Therapeutics…

Autolus Therapeutics announced that Martin Murphy was appointed as non-executive chairman of its board of directors, effective April 15. Christian Itin has chaired the Autolus board of directors since the company's inception in 2014 and has also served as CEO since 2016. As the company's lead program, AUTO1, continues to progress in multiple clinical trials and the company starts to prepare for commercialization in the event that AUTO1 receives marketing approval, the company "believes that the complexity of the business warrants separation of the roles of chairman and CEO, enabling Itin to fully focus on leading the business," the company said. Itin will remain a member of the Autolus board. Murphy has more than 25 years of experience in the life science sector and joined the Autolus Board as a non-executive director at the time of the company's inception in 2014.

ShowHide Related Items >><<
AUTL Autolus Therapeutics
$5.28 /

-0.25 (-4.52%)

AUTL Autolus Therapeutics
$5.28 /

-0.25 (-4.52%)

03/10/21 Redburn
Autolus Therapeutics downgraded to Neutral from Buy at Redburn
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral with $9 target at JPMorgan
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral from Overweight at JPMorgan
01/07/21 Truist
Autolus Therapeutics price target lowered to $15 from $30 at Truist
AUTL Autolus Therapeutics
$5.28 /

-0.25 (-4.52%)

  • 10
    Feb
Conference/Events
William Blair biotech analysts to hold an analyst/industry conference call » 16:10
04/16/21
04/16
16:10
04/16/21
16:10
AUTL

Autolus Therapeutics

$5.30 /

-0.23 (-4.16%)

Biotech Analysts, along…

Biotech Analysts, along with Dr. Marks, Director of the Bristol Allogeneic Adult Bone Marrow Transplant Unit, will discuss Autolus' potentially pivotal Phase II FELIX study of AUTO1 in adult Acute Lymphoblastic Leukemia (ALL) on an Analyst/Industry conference call to be held on April 20 at 8 am.

ShowHide Related Items >><<
AUTL Autolus Therapeutics
$5.30 /

-0.23 (-4.16%)

AUTL Autolus Therapeutics
$5.30 /

-0.23 (-4.16%)

03/10/21 Redburn
Autolus Therapeutics downgraded to Neutral from Buy at Redburn
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral with $9 target at JPMorgan
01/29/21 JPMorgan
Autolus Therapeutics downgraded to Neutral from Overweight at JPMorgan
01/07/21 Truist
Autolus Therapeutics price target lowered to $15 from $30 at Truist
AUTL Autolus Therapeutics
$5.30 /

-0.23 (-4.16%)

  • 10
    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.